Helius Medical Technologies Secures VA Contract for PoNS System

Helius Medical Technologies Makes Headway with VA Healthcare System

Helius Medical Technologies, Inc. (NASDAQ: HSDT), a standout in the neurotechnology field, continues to advance its footprint in the market by announcing a significant milestone: the sale of its first Portable Neuromodulation Stimulator (PoNS) System to the Veterans Affairs (VA) Healthcare System. This sale, through the trusted distributor Lovell Government Services, was finalized at a total price of $23,844, made up of the PoNS Controller priced at $16,499 and the PoNS Mouthpiece at $7,345.

Importance of the PoNS System for Veterans

The announcement has been met with enthusiasm from both Helius and the VA. Helius’ President and Chief Executive Officer, Dane Andreeff, expressed pride in the achievement, emphasizing that the sale opens doors to better treatment options for veterans experiencing gait deficits due to multiple sclerosis (MS). With an estimated 55,000 to 70,000 veterans in the U.S. grappling with this condition, the PoNS System aims to provide an innovative solution. The integration of the PoNS into the VA’s medical offerings signifies a promising avenue for expanding treatment access among this important demographic.

Streamlining Operations within the VA

Since the PoNS system’s approval for the Federal Supply Schedule contract, efforts have been underway to establish Helius as an approved vendor within the VA, facilitating a smoother operational framework for future transactions. The first sale marks not just a financial success but also a strategic entry point into a broader market of veterans needing effective therapeutic interventions.

Expanding Coverage and Support

Helius is dedicated to enhancing its presence across various VA locations, particularly in the eastern and southeastern U.S. The company’s team of independent sales professionals is actively working to extend coverage to all VA MS Centers of Excellence (MSCoE) across the nation. This proactive approach signals Helius’ commitment to supporting veterans with innovative therapies tailored for their needs.

Understanding PoNS Therapy

The Portable Neuromodulation Stimulator is a non-implantable device that delivers neurostimulation through an oral application. Used primarily during physical rehabilitation, it functions to enhance balance and improve gait for adults with mild to moderate responses to MS. This device, which emits mild electrical impulses, is recommended for individuals over the age of 22 and is to be utilized in conjunction with a prescribed therapy regime.

Clinical Efficacy in Other Regions

In Canada, the PoNS therapy has demonstrated effectiveness in reducing gait issues and balance challenges, significantly lowering fall risks among stroke patients. Authorized for multiple indications, the device has been pivotal in addressing the needs of individuals recovering from various neurological conditions. Additionally, the PoNS system's design fosters improved outcomes when paired with supervised therapeutic exercises, reinforcing its value in clinical settings.

Global Reach of the PoNS Device

Beyond the United States, the PoNS system is also recognized in Australia, where it is available for short-term therapeutic use, further broadening its global influence. Helius’ commitment to enhancing neuroplasticity through innovative methods continues to position it as a leader in its field.

Company Overview: Helius Medical Technologies

Helius Medical Technologies, recognized for its pioneering efforts in treating neurological deficits, leverages its groundbreaking technology to improve the quality of life for individuals affected by neurologic disorders. By focusing on devices that stimulate brain mechanisms and promote neuroplasticity, the company stands at the forefront of neurotherapy.

Building Relationships with Veterans

The company’s recent collaboration with Lovell Government Services exemplifies its commitment to serving veteran populations. Lovell, a trusted partner, has been delivering value to federal healthcare markets since 2013, strengthening connections between medical providers and government entities. This partnership enhances Helius’ ability to serve those who have bravely served the country, emphasizing a shared mission focused on patient care.

Frequently Asked Questions

What is the PoNS System?

The PoNS System is a Portable Neuromodulation Stimulator designed to treat gait deficits in adults with mild to moderate symptoms from multiple sclerosis when used alongside physical therapy.

How does Helius Medical Technologies support veterans?

Helius Medical Technologies supports veterans by providing innovative treatment options like the PoNS System, aiming to improve their quality of life through advanced therapies.

What are the benefits of using the PoNS device?

The PoNS device helps improve balance and gait while reducing the risk of falls, facilitating better outcomes for patients undergoing rehabilitation.

Where can I learn more about Helius Medical Technologies?

For more information about Helius and the PoNS device, please visit their official website.

How has the PoNS System been received in other countries?

In Canada and Australia, the PoNS System has been authorized for use in treating various conditions and has demonstrated significant clinical efficacy in improving patient outcomes.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.